Forgot Password

Thank you for your request!

We will soon reach out to you.

Thank you for downloading..!

Contact us for more information.
Home » Healthcare » Medical Diagnostics » HME-8891217
  • Global Plasma Therapy Market-Technologies, Market share and Industry Forecast to 2024

  • Publish: December 2017 | Report Code: HME-8891217

* For discount/customization and buying a particular chapter click here or write to us at sales@occamsresearch.com

Plasma therapy is referred as the treatment of blood cells by using platelet rich plasma which is  centrifuged to remove the red blood cells. The global plasma therapy market is expected to rise at a CAGR of 14.5% during the forecast period 2016-2023. These blood plasmas have higher concentration of growth factors as compared to whole blood thus it is specifically used in dentistry, dermatology and orthopedics. It is also helful in the treatment of acute muscle strains, muscle-fascial injuries, tendinopathy and osteoarthritis.

The increasing number of sports related injuries has increased the demand for plasma therapy. According to U.S. Centers for Disease Control (CDC), approximately 30 million children and teenagers participate in the youth sports organized in U.S. High School athletes are suffered from approximately 2 million injuries and over 500,000 visits to doctor and about 30,000 hospitalizations every year. About 20% of children aged between 8 to 12 years and 45% of children aged between 13 to 14 years suffer from arm pain during the single youth baseball season. Furthermore, according to National Federation of High School Associations, high school players who play a single sport are 70% more vulnerable to bone injury than those who play other games. It is evident that young children participating in the sports, such as soccer, baseball, etc. are more prevalent to suffer from knee injuries at young age. Moreover, sports injuries among the adolescents have been termed as ‘silent epidemic’ as these injuries may get healed temporarily but it may prove to be painful in the long run. Moreover, according to the American Academy of Paediatrics, the most prevalent knee injuries among the adolescent players are tears in the medial collateral ligament, further followed by the ACL and the meniscus.

Source: OBRC Analysis.

The report on global plasma therapy market includes segments based on type, source, applications and end users.

Types of plasma used in plasma therapy include:

  • Pure Platelet Rich Plasma
  • Leukocyte-Rich Platelet Rich Plasma
  • Pure Platelet-Rich Fibrin
  • Leukocyte-Rich Fibrin





Source of plasma therapy includes:

  • Autologous
  • Allogenic



 The applications of plasma therapy include:

  • Orthopedic
  • Dermatology
  • Cardiac Muscle Injury
  • Dental
  • Nerve Injury
  • Others







End users of plasma therapy include:

  • Hospitals & Clinics
  • Research Institutes



The report scope is widely categorized on the basis of its types which include pure platelet rich plasma, leukocyte-rich platelet rich plasma, pure platelet-rich fibrin and leukocyte-rich fibrin.

The global plasma therapy market report has been geographically segmented in:

  • North America (U.S. & Canada)
  • Asia Pacific (China, India, Japan, RoAPAC)
  • Europe (UK, France, Germany, RoE)
  • Rest of World





Geographically, North America is the leading market for global plasma therapy in terms of market revenue share. The key factors driving the market growth in North America is the rising number of incidences of sports injuries and orthopaedic diseases.  Moreover, the availability of advanced healthcare facilities along with improved diagnostics has driven the market growth in North America. However, Asia Pacific is expected to emerge as the fastest growing market region during forecast period. This is due to the increasing geriatric population which has led to surging demand for cosmetic surgeries.

Global plasma therapy market report covers segmentation analysis of type, source, applications and end users. Report further covers segments of types of plasma which includes pure platelet rich plasma, leukocyte-rich platelet rich plasma, pure platelet-rich fibrin and leukocyte-rich fibrin. The pure platelet rich plasma is leading type segment as it has higher number of platelets as compared to the commonly used variants of platelet rich plasma. Also it has effective antimicrobial effects and high success rate. However, leucocyte-rich platelet rich plasma is expected to be the fastest growing segment. Report further covers segments of source which includes autologous and allogenic. Autologous is the leading source segment owing to the rising prevalence of orthopaedic disorders, such as tendinitis and arthritis which has led to surging demand for advanced treatment options. The applications of plasma therapy include orthopedic, dermatology, cardiac muscle injury, dental, nerve injury etc. The dermatology is the leading application segment owing to the surging demand for cosmetic surgeries and procedures. The end users of plasma therapy include hospitals & clinics and research institutes. The hospitals & clinics is the largest end user segment owing to the increasing healthcare expenditure.

The major market players of the global plasma therapy market are:

  • ARTHREX
  • BIOLIFE PLASMA SERVICES
  • CAMBRYN BIOLOGICS LLC
  • DEPUY SYNTHES INC.
  • HARVEST TECHNOLOGIES CORP
  • OTHERS







These companies are using various strategies, such as merger & acquisition, collaboration, partnership and product launch. Whereas, product and service launch is the key strategy adopted by the companies in the plasma therapy market.

For Example; In July 2017, Arthrex had introduced its Arthrex ACP Double Syringe System which provides efficient and rapid concentration of platelets. Moreover this system requires minimum amount of blood which reduces the time for platelet rich plasma treatment.

In December 2016, Cambryn Biologics had announced that it would be expanding its current plasma manufacturing facility by 30% which would increase the annual capacity of company to an approximately 75,000 litre per year.

The report covers detailed analysis of companies which comprises overview, SCOT analysis, product portfolio, strategic initiative, strategic analysis, competitive landscape and market share analysis in plasma therapy market.

Key reason to buy the report:

  • The report includes market estimation, forecast and analysis for the year 2016-2023
  • Report includes detailed analysis of different segments, such as type, source, applications and end users of global plasma therapy market.
  • Identify and understand the strengths, opportunities, challenges and threats of the global plasma therapy market.
  • Covers detailed analysis of Porters 5 force model and other strategic models and also covers revenues, market share analysis, and competitive landscape analysis of major players of global plasma therapy market.
  • Detailed analysis of various regulatory policies which are affecting the global plasma therapy market.






How we are different from others:

At Occam’s we provide an extensive portfolio which is comprehensive market analysis along with the market size, market share and market segmentations. Our report on global plasma therapy market offers detailed analysis of strategic models, such as investment vs. adoption model, see saw analysis and others strategic models. Also, the report contains the detailed analysis of application, adoption scenario and decision support for each segment. The report discusses competitive landscape of the plasma therapy market with extensive SCOT analysis of key companies. 

Key findings of the global plasma therapy market:

  • The key factor driving the market growth is the increasing number of sports related injuries.
  • North America is the leading market for global plasma therapy in terms of market revenue share.
  • The pure platelet rich plasma is leading type segment as it has higher number of platelets as compared to the commonly used variants of platelet rich plasma.
  • Product and service launch is the key strategy adopted by the companies in the global plasma therapy market.
1. INTRODUCTION
1.1. EXECUTIVE SUMMARY
1.2. ESTIMATION METHODOLOGY
 
2. MARKET OVERVIEW
2.1. GLOBAL  PLASMA THERAPY  MARKET : EVOLUTION & TRANSITION
2.2. MARKET DEFINITION & SCOPE
2.3. INDUSTRY STRUCTURE
2.4. REGULATORY FRAMEWORK
2.5. TOTAL MARKET ANALYSIS
2.5.1. TOP 5 FINDINGS
2.5.2. TOP 5 OPPORTUNITY MARKETS
2.5.3. TOP 5 COMPANIES
2.5.4. TOP 3 COMPETITIVE STRATEGIES
2.6. ESTIMATION ANALYSIS
2.7. STRATEGIC ANALYSIS
2.7.1. INVESTMENT VS. ADOPTION MODEL
2.7.2. 360-DEGREE INDUSTRY ANALYSIS
2.7.3. PORTERS 5 FORCE MODEL
2.7.4. SEE-SAW ANALYSIS
2.7.5. CONSUMER ANALYSIS AND KEY BUYING CRITERIA
2.8. COMPETITIVE ANALYSIS
2.8.1. KEY STRATEGIES & ANALYSIS
2.8.2. MARKET SHARE ANALYSIS & TOP COMPANY ANALYSIS
2.9. STRATEGIC RECOMMENDATIONS & KEY CONCLUSIONS
2.9.1. INVESTMENT OPPORTUNITIES BY REGIONS
2.9.2. OPPORTUNITIES IN EMERGING APPLICATIONS
2.9.3. INVESTMENT OPPORTUNITY IN FASTEST GROWING SEGMENT
 
3. MARKET DETERMINANTS 
3.1. MARKET DRIVERS
3.1.1. INCREASING INCIDENCES OF SPORTS RELATED INJURIES 
3.1.2. RISING NUMBER OF ANDROGENIC ALOPECIA PATIENTS WORLDWIDE
3.1.3. RAPID DEPLOYMENT OF PLATELET-RICH PLASMA IN VARIOUS THERAPEUTIC AREAS
3.1.4. INCREASING PREVALENCE OF ARTHRITIS
3.2. MARKET RESTRAINTS
3.2.1. INSUFFICIENT REIMBURSEMENT POLICIES
3.2.2. FLUCTUATING PRICES OF PLASMA THERAPY
3.3. MARKET OPPORTUNITIES
3.3.1. INCREASING PREVALENCE OF  ORTHOPEDIC DISORDERS
3.4.   MARKET CHALLENGES 
3.4.1. LIMITED USAGE OF PLATELET RICH PLASMA FOR DIABETIC AND KIDNEY PATIENTS
3.4.2. DEVELOPMENTS IN REGENERATIVE MEDICINE
 
4. MARKET SEGMENTATION
4.1. GLOBAL PLASMA THERAPY MARKET BY TYPE
4.1.1. MARKET DEFINITION AND SCOPE
4.1.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.1.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.1.4. OPPORTUNITY MATRIX
4.1.5. MARKET SEGMENTATION 
4.1.5.1. GLOBAL  PURE PLATELET RICH PLASMA  MARKET 
4.1.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.1.5.1.3. KEY PLAYERS & KEY PRODUCTS 
4.1.5.1.4. KEY CONCLUSIONS
4.1.5.2. GLOBAL LEUKOCYTE-RICH PLATELET RICH PLASMA  MARKET 
4.1.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.1.5.2.3. KEY PLAYERS & KEY PRODUCTS 
4.1.5.2.4. KEY CONCLUSIONS
4.1.5.3. GLOBAL  PURE PLATELET-RICH FIBRIN MARKET 
4.1.5.3.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.3.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.1.5.3.3. KEY PLAYERS & KEY PRODUCTS 
4.1.5.3.4. KEY CONCLUSIONS
4.1.5.4. GLOBAL LEUKOCYTE-RICH FIBRIN MARKET 
4.1.5.4.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.4.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.1.5.4.3. KEY PLAYERS & KEY PRODUCTS 
4.1.5.4.4. KEY CONCLUSIONS
4.2. GLOBAL PLASMA THERAPY MARKET BY SOURCE
4.2.1. MARKET DEFINITION AND SCOPE
4.2.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.2.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.2.4. OPPORTUNITY MATRIX
4.2.5. MARKET SEGMENTATION 
4.2.5.1. GLOBAL    AUTOLOGOUS MARKET 
4.2.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.1.3. KEY PLAYERS & KEY PRODUCTS 
4.2.5.1.4. KEY CONCLUSIONS
4.2.5.2. GLOBAL  ALLOGENIC MARKET 
4.2.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.2.3. KEY PLAYERS & KEY PRODUCTS 
4.2.5.2.4. KEY CONCLUSIONS
4.3. GLOBAL PLASMA THERAPY  MARKET BY APPLICATION
4.3.1. MARKET DEFINITION AND SCOPE
4.3.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.3.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.3.4. OPPORTUNITY MATRIX
4.3.5. MARKET SEGMENTATION 
4.3.5.1. GLOBAL  ORTHOPEDIC MARKET 
4.3.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.1.3. KEY  PLAYERS & KEY PRODUCTS 
4.3.5.1.4. KEY CONCLUSIONS
4.3.5.2. GLOBAL DERMATOLOGY  MARKET 
4.3.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.2.3. KEY PLAYERS & KEY PRODUCTS 
4.3.5.2.4. KEY CONCLUSIONS
4.3.5.3. GLOBAL  CARDIAC MUSCLE INJURY  MARKET 
4.3.5.3.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.3.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.3.3. KEY  PLAYERS & KEY PRODUCTS 
4.3.5.3.4. KEY CONCLUSIONS
4.3.5.4. GLOBAL DENTAL  MARKET 
4.3.5.4.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.4.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.4.3. KEY PLAYERS & KEY PRODUCTS 
4.3.5.4.4. KEY CONCLUSIONS
4.3.5.5. GLOBAL NERVE INJURY  MARKET 
4.3.5.5.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.5.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.5.3. KEY PLAYERS & KEY PRODUCTS 
4.3.5.5.4. KEY CONCLUSIONS
4.3.5.6. GLOBAL  OTHER APPLICATIONS  MARKET 
4.3.5.6.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.6.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.6.3. KEY  PLAYERS & KEY PRODUCTS 
4.3.5.6.4. KEY CONCLUSIONS
4.4. GLOBAL PLASMA THERAPY  MARKET BY END USERS
4.4.1. MARKET DEFINITION AND SCOPE
4.4.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.4.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.4.4. OPPORTUNITY MATRIX
4.4.5. MARKET SEGMENTATION 
4.4.5.1. GLOBAL  HOSPITALS & CLINICS  MARKET 
4.4.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.4.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.4.5.1.3. KEY  PLAYERS & KEY PRODUCTS 
4.4.5.1.4. KEY CONCLUSIONS
4.4.5.2. GLOBAL RESEARCH INSTITUTES  MARKET 
4.4.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.4.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.4.5.2.3. KEY PLAYERS & KEY PRODUCTS 
4.4.5.2.4. KEY CONCLUSIONS
 
5. COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES
5.1.1. LIST OF MERGERS AND ACQUISITION
5.1.2. LIST OF JOINT VENTURES
5.1.3. LIST OF PRODUCT LAUNCHES
5.1.4. LIST OF PARTNERSHIPS
 
6. GEOGRAPHIC ANALYSIS
6.1. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
6.2. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
6.3. OPPORTUNITY MATRIX
6.4. GLOBAL PLASMA THERAPY MARKET BY REGION 2014-2023 ($ MILLION)
6.4.1. NORTH AMERICA
6.4.1.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
6.4.1.2. TOP COUNTRY ANALYSIS
6.4.1.2.1. U.S. 
6.4.1.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.1.2.1.2. KEY PLAYERS & KEY PRODUCTS
6.4.1.2.1.3. KEY CONCLUSIONS
6.4.1.2.2. CANADA
6.4.1.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.1.2.2.2. KEY PLAYERS & KEY PRODUCTS
6.4.1.2.2.3. KEY CONCLUSIONS
6.4.2. EUROPE
6.4.2.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
6.4.2.2. TOP COUNTRY ANALYSIS
6.4.2.2.1. UK
6.4.2.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.1.2. KEY PLAYERS & KEY PRODUCTS
6.4.2.2.1.3. KEY CONCLUSIONS
6.4.2.2.2. FRANCE
6.4.2.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.2.2. KEY PLAYERS & KEY PRODUCTS
6.4.2.2.2.3. KEY CONCLUSIONS
6.4.2.2.3. GERMANY
6.4.2.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.3.2. KEY PLAYERS & KEY PRODUCTS
6.4.2.2.3.3. KEY CONCLUSIONS
6.4.2.2.4. SPAIN
6.4.2.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.4.2. KEY PLAYERS & KEY PRODUCTS
6.4.2.2.4.3. KEY CONCLUSIONS
6.4.2.2.5. REST OF EUROPE
6.4.2.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.5.2. KEY  PLAYERS & KEY PRODUCTS
6.4.2.2.5.3. KEY CONCLUSIONS
6.4.3. ASIA PACIFIC
6.4.3.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
6.4.3.2. TOP COUNTRY ANALYSIS
6.4.3.2.1. CHINA
6.4.3.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.1.2. KEY PLAYERS & KEY PRODUCTS
6.4.3.2.1.3. KEY CONCLUSIONS
6.4.3.2.2. INDIA
6.4.3.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.2.2. KEY PLAYERS & KEY PRODUCTS
6.4.3.2.2.3. KEY CONCLUSIONS
6.4.3.2.3. JAPAN
6.4.3.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.3.2. KEY PLAYERS & KEY PRODUCTS
6.4.3.2.3.3. KEY CONCLUSIONS
6.4.3.2.4. AUSTRALIA
6.4.3.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.4.2. KEY  PLAYERS & KEY PRODUCTS
6.4.3.2.4.3. KEY CONCLUSIONS
6.4.3.2.5. REST OF ASIA PACIFIC
6.4.3.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.5.2. KEY  PLAYERS & KEY PRODUCTS
6.4.3.2.5.3. KEY CONCLUSIONS
6.4.4. ROW
6.4.4.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
6.4.4.2. TOP COUNTRY ANALYSIS
6.4.4.2.1. LATIN AMERICA
6.4.4.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.4.2.1.2. KEY PLAYERS & KEY PRODUCTS
6.4.4.2.1.3. KEY CONCLUSIONS
6.4.4.2.2. MIDDLE EAST & AFRICA 
6.4.4.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.4.2.2.2. KEY PLAYERS & KEY PRODUCTS
6.4.4.2.2.3. KEY CONCLUSIONS
 
7. COMPANY PROFILES
7.1. ARTHREX (U.S.)
7.1.1. OVERVIEW
7.1.2. PRODUCT PORTFOLIO
7.1.3. STRATEGIC INITIATIVES 
7.1.4. SCOT ANALYSIS
7.1.5. STRATEGIC ANALYSIS
7.2. BIOLIFE PLASMA SERVICES (U.S.)
7.2.1. OVERVIEW
7.2.2. PRODUCT PORTFOLIO
7.2.3. STRATEGIC INITIATIVES 
7.2.4. SCOT ANALYSIS
7.2.5. STRATEGIC ANALYSIS
7.3. BIO PRODUCT LABORATORY LTD. (U.K.)
7.3.1. OVERVIEW
7.3.2. PRODUCT PORTFOLIO
7.3.3. STRATEGIC INITIATIVES 
7.3.4. SCOT ANALYSIS
7.3.5. STRATEGIC ANALYSIS
7.4. BIOTEST (GERMANY)
7.4.1. OVERVIEW
7.4.2. PRODUCT PORTFOLIO
7.4.3. STRATEGIC INITIATIVES 
7.4.4. SCOT ANALYSIS 
7.4.5. STRATEGIC ANALYSIS
7.5.   CAMBRYN BIOLOGICS LLC (U.S.)
7.5.1. OVERVIEW
7.5.2. PRODUCT PORTFOLIO
7.5.3. STRATEGIC INITIATIVES 
7.5.4. SCOT ANALYSIS
7.5.5. STRATEGIC ANALYSIS
7.6. CHINA BIOLOGIC PRODUCTS INC. (CHINA)
7.6.1. OVERVIEW
7.6.2. PRODUCT PORTFOLIO
7.6.3. STRATEGIC INITIATIVES 
7.6.4. SCOT ANALYSIS
7.6.5. STRATEGIC ANALYSIS
7.7. CSL LTD. (U.S.)
7.7.1. OVERVIEW
7.7.2. PRODUCT PORTFOLIO
7.7.3. STRATEGIC INITIATIVES 
7.7.4. SCOT ANALYSIS
7.7.5. STRATEGIC ANALYSIS
7.8. DEPUY SYNTHES INC. (U.S.)
7.8.1. OVERVIEW
7.8.2. PRODUCT PORTFOLIO
7.8.3. STRATEGIC INITIATIVES 
7.8.4. SCOT ANALYSIS 
7.8.5. STRATEGIC ANALYSIS
7.9. GRIFOLS INTERNATIONAL S.A. (AUSTRALIA)
7.9.1. OVERVIEW
7.9.2. PRODUCT PORTFOLIO
7.9.3. STRATEGIC INITIATIVES 
7.9.4. SCOT ANALYSIS 
7.9.5. STRATEGIC ANALYSIS
7.10. HARVEST TECHNOLOGIES CORP (U.S.)
7.10.1. OVERVIEW
7.10.2. PRODUCT PORTFOLIO
7.10.3. STRATEGIC INITIATIVES 
7.10.4. SCOT ANALYSIS
7.10.5. STRATEGIC ANALYSIS
7.11. KEDRION S.P.A. (ITALY)
7.11.1. OVERVIEW
7.11.2. PRODUCT PORTFOLIO
7.11.3. STRATEGIC INITIATIVES 
7.11.4. SCOT ANALYSIS
7.11.5. STRATEGIC ANALYSIS
7.12. LFB SA (FRANCE)
7.12.1. OVERVIEW
7.12.2. PRODUCT PORTFOLIO
7.12.3. STRATEGIC INITIATIVES 
7.12.4. SCOT ANALYSIS
7.12.5. STRATEGIC ANALYSIS
7.13. OCTAPHARMA (SWITZERLAND)
7.13.1. OVERVIEW
7.13.2. PRODUCT PORTFOLIO
7.13.3. STRATEGIC INITIATIVES 
7.13.4. SCOT ANALYSIS
7.13.5. STRATEGIC ANALYSIS
7.14. REGEN LAB SA (SWITZERLAND)
7.14.1. OVERVIEW
7.14.2. PRODUCT PORTFOLIO
7.14.3. STRATEGIC INITIATIVES 
7.14.4. SCOT ANALYSIS
7.14.5. STRATEGIC ANALYSIS
7.15. STRYKER CORPORATION (U.S.)
7.15.1. OVERVIEW
7.15.2. PRODUCT PORTFOLIO
7.15.3. STRATEGIC INITIATIVES 
7.15.4. SCOT ANALYSIS
7.15.5. STRATEGIC ANALYSIS
 
LIST OF TABLES
 
1. GLOBAL PLASMA THERAPY MARKET BY TYPE  2014-2023 ($ MILLION)
2. GLOBAL PURE PLATELET RICH PLASMA MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
3. GLOBAL LEUKOCYTE-RICH PLATELET RICH PLASMA MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
4. GLOBAL  PURE PLATELET-RICH FIBRIN MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
5. GLOBAL LEUKOCYTE-RICH FIBRIN MARKET  BY GEOGRAPHY 2014-2023 ($ MILLION)
6. GLOBAL PLASMA THERAPY MARKET BY SOURCE  2014-2023 ($ MILLION)
7. GLOBAL AUTOLOGOUS MARKET  BY GEOGRAPHY 2014-2023 ($ MILLION)
8. GLOBAL  ALLOGENIC MARKET  BY GEOGRAPHY 2014-2023 ($ MILLION)
9. GLOBAL PLASMA THERAPY MARKET BY APPLICATIONS 2014-2023 ($ MILLION)
10. GLOBAL ORTHOPEDIC  MARKET  BY GEOGRAPHY 2014-2023 ($ MILLION)
11. GLOBAL  DERMATOLOGY  MARKET  BY GEOGRAPHY 2014-2023 ($ MILLION)
12. GLOBAL CARDIAC MUSCLE INJURY  MARKET  BY GEOGRAPHY 2014-2023 ($ MILLION)
13. GLOBAL DENTAL  MARKET  BY GEOGRAPHY 2014-2023 ($ MILLION)
14. GLOBAL  NERVE INJURY  MARKET  BY GEOGRAPHY 2014-2023 ($ MILLION)
15. GLOBAL  OTHER APPLICATIONS MARKET  BY GEOGRAPHY 2014-2023 ($ MILLION)
16. GLOBAL PLASMA THERAPY MARKET BY END USERS 2014-2023 ($ MILLION)
17. GLOBAL HOSPITALS & CLINICS MARKET  BY GEOGRAPHY 2014-2023 ($ MILLION)
18. GLOBAL  RESEARCH INSTITUTES  MARKET  BY GEOGRAPHY 2014-2023 ($ MILLION)
19. NORTH AMERICA PLASMA THERAPY MARKET 2014-2023 ($ MILLION)
20. EUROPE PLASMA THERAPY  MARKET 2014-2023 ($ MILLION)
21. ASIA PACIFIC PLASMA THERAPY MARKET 2014-2023 ($ MILLION)
22. REST OF THE WORLD PLASMA THERAPY MARKET 2014-2023 ($ MILLION)
 
LIST OF FIGURES
 
1. GLOBAL PURE PLATELET RICH PLASMA MARKET 2014-2023 ($ MILLION)
2. GLOBAL LEUKOCYTE-RICH PLATELET RICH PLASMA MARKET 2014-2023 ($ MILLION)
3. GLOBAL  PURE PLATELET-RICH FIBRIN MARKET  2014-2023 ($ MILLION)
4. GLOBAL LEUKOCYTE-RICH FIBRIN MARKET   2014-2023 ($ MILLION)
5. GLOBAL AUTOLOGOUS MARKET   2014-2023 ($ MILLION)
6. GLOBAL  ALLOGENIC MARKET   2014-2023 ($ MILLION)
7. GLOBAL ORTHOPEDIC  MARKET   2014-2023 ($ MILLION)
8. GLOBAL  DERMATOLOGY  MARKET   2014-2023 ($ MILLION)
9. GLOBAL CARDIAC MUSCLE INJURY  MARKET   2014-2023 ($ MILLION)
10. GLOBAL DENTAL  MARKET   2014-2023 ($ MILLION)
11. GLOBAL  NERVE INJURY  MARKET   2014-2023 ($ MILLION)
12. GLOBAL  OTHER APPLICATIONS MARKET   2014-2023 ($ MILLION)
13. GLOBAL HOSPITALS & CLINICS MARKET   2014-2023 ($ MILLION)
14. GLOBAL  RESEARCH INSTITUTES  MARKET   2014-2023 ($ MILLION)
15. UNITED STATES (U.S.) PLASMA THERAPY  MARKET 2014-2023 ($ MILLION)
16. CANADA PLASMA THERAPY  MARKET 2014-2023 ($ MILLION)
17. UNITED KINGDOM (UK) PLASMA THERAPY MARKET 2014-2023 ($ MILLION)
18. FRANCE PLASMA THERAPY  MARKET 2014-2023 ($ MILLION)
19. GERMANY PLASMA THERAPY MARKET 2014-2023 ($ MILLION)
20. SPAIN PLASMA THERAPY MARKET 2014-2023 ($ MILLION)
21. ROE PLASMA THERAPY MARKET 2014-2023 ($ MILLION)
22. INDIA PLASMA THERAPY MARKET 2014-2023 ($ MILLION)
23. CHINA PLASMA THERAPY MARKET 2014-2023 ($ MILLION)
24. JAPAN PLASMA THERAPY MARKET 2014-2023 ($ MILLION)
25. AUSTRALIA PLASMA THERAPY MARKET 2014-2023 ($ MILLION)
26. ROAPAC PLASMA THERAPY MARKET 2014-2023 ($ MILLION)
27. LATIN AMERICA PLASMA THERAPY MARKET 2014-2023 ($ MILLION)
28. MENA PLASMA THERAPY MARKET 2014-2023 ($ MILLION)
 

FAQ

How can I purchase a report?
We offer an easy way to purchase any report of your choice from various domains that we offer. You can easily search for your desired reports by simply using the search bar on our website's home page. For multiple purchases, you can add reports to the shopping cart, fill a detail form and check out. We accept payments though authentic and trusted payment gateways which accept all major credit cards.
How safe is to use my credit card? Is my information secure?
We ensure complete safety to all online transactions made by credit cards. We use most secure encryption technology available today for the electronic transactions and all our credit card sales are secured with an SSL technology. Your information is highly secure and confidential.
Can I get a discount?
We send discount offers through email as per your request. In case you would like to receive discounts, please sign up for our newsletter.
I want to buy only a chapter. I don't need complete report.
Yes you can buy your desired chapter/page or the entire report, by just clicking on the table of contents in any report and selecting chapter of your interest. We do have separate pricing for chapters/reports/excel sheets/presentation pages etc.
Can I get reports on my desired topic specially which is not available in your current portfolio?
Do call us or mail us the topic of your preference. Our dedicated team on analysts will prepare a report as per your preference and requirements.
When do I get access to the report(s) that I have purchased?
We will email you your purchased report right after we receive your payment through any of the payment options.
Will I receive any invoice for my purchase?
Yes we will email you invoice/payment confirmation with the order details once we receive your payment.
In what format will the reports be available in?
All the reports will be available in PDF format for download.

Request for Sample


UPCOMING REPORTS

No upcoming reports available under this subcategory.

CONNECT WITH US

Occams Business Research & Consulting Pvt. Ltd.

Landline: 0731 4042636 

Handheld: +91 8390547755

Email: info@occamsresearch.com

 

 

Go To Top
viewthroughconversion